How the new coronavirus variant quickly accumulated 17 mutations

Immunocompromised patients experiencing prolonged infection with novel coronavirus when treated with convalescent plasma might trigger a strong selective pressure on the virus due to high concentration of antibodies. This might lead to the generation of large number of mutations. The new SARS-CoV-2 variant — B.1.1.7 — that was first seen in Kent and Greater London … Continue reading How the new coronavirus variant quickly accumulated 17 mutations

Plasma therapy: In a welcome change, ICMR insists on evidence-based approach

ICMR’s insistence on an evidence-based approach to plasma therapy is a welcome change and is in stark contrast to the cavalier manner in which it approved hydroxychloroquine as a prophylaxis for coronavirus without carrying out any trial and relying on evidence which was slim and dodgy and that too only for treatment, and also when … Continue reading Plasma therapy: In a welcome change, ICMR insists on evidence-based approach

Convalescent plasma therapy tested on critically ill COVID-19 patients

A pharma company in China is testing convalescent plasma therapy to treat critically sick COVID-19 patients. So far, 13 patients have been treated and some improvements in clinical symptoms have been seen. In the absence of any preventive vaccine or specific antivirals for treating COVID-19 patients infected with the novel coronavirus SARS-CoV-2, a pharmaceutical company … Continue reading Convalescent plasma therapy tested on critically ill COVID-19 patients

An Ebola cloud with a silver lining

At the height of West African Ebola epidemic in 2014, the medicine chest was all but empty; no approved drug was available to facilititate treatment. With no signs of the disease abating and the fatality rate hovering around 70 per cent, the World Health Organization (WHO) in August 2014 declared that it was not unethical … Continue reading An Ebola cloud with a silver lining